Govorestat

Govorestat
Clinical data
Other names	AT-007
ATC code	A16AX24 (WHO) ;
Identifiers
	IUPAC name 2-[4-Oxo-3-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl]thieno[3,4-d]pyridazin-1-yl]acetic acid;
CAS Number	2170729-29-8;
PubChem CID	132260161;
DrugBank	DB16707;
ChemSpider	81409264;
UNII	6JLQ8K35KK;
ChEMBL	ChEMBL4650327;
Chemical and physical data
Formula	C17H10F3N3O3S2
Molar mass	425.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC2=C(C=C1C(F)(F)F)N=C(S2)CN3C(=O)C4=CSC=C4C(=N3)CC(=O)O;
	InChI InChI=1S/C17H10F3N3O3S2/c18-17(19,20)8-1-2-13-12(3-8)21-14(28-13)5-23-16(26)10-7-27-6-9(10)11(22-23)4-15(24)25/h1-3,6-7H,4-5H2,(H,24,25); Key:ORQGHAJIWGGFJK-UHFFFAOYSA-N;

Govorestat (AT-007) is an aldose reductase inhibitor and experimental drug to treat galactosemia^[1] and sorbitol dehydrogenase deficiency.^[2]

After a report circulating on the internet accused the developer Applied Therapeutics of cutting corners in its studies of the drug, the FDA put a hold on it in 2020. Applied Therapeutics said that the report was a fraudulent attempt to manipulate its stock price.^[3]

In February 2024, the FDA granted priority review states to an application from Applied Therapeutics to use govorestat to treat galactosemia, a metabolic disease.^[4] The FDA then rejected the company’s application in November 2024, and issued a warning letter to then-President Shoshana Shendelman informing her of “objectionable conditions” observed during an FDA inspection earlier that year.^[5]

Society and culture

Legal status

In December 2024, Advanz Pharma Limited withdrew its application for a marketing authorization of Nugalviq for the treatment of classic galactosaemia, a condition where the body cannot break down a sugar called galactose.^[6]